Parkinson’s Disease (PD) is an irreversible degenerative neurological disorder with no known cure. Apomorphine is a potent short-acting D1/D2 dopamine agonist administered sub-cutaneously that is used in the treatment of PD. Optimising PD medication is an important aspect of end of life care. There are no previously reported cases of apomorphine providing symptom relief in terminal care of PD patients. This case highlights its potential benefits for symptom control at the end of life.
Tanner CMEpidemiology of Parkinson’s disease. Neurol Clin1992; 10: 317-329.
2.
MacMahon DG, Thomas S.Practical approaches to quality of life in Parkinson’s Disease: the nurses role. J Neurol1998; 245(suppl 1): S19-S22.
3.
National Institute of Clinical Excellence.Parkinson’s Disease: Diagnosis and Management in Primary and Secondary Care, 2005. http://www.nice.org.uk/page.aspx?o=267744
4.
Lee MA, Walker RW, Hildreth AJ, Prentice WMA survey of pain in idiopathic Parkinson’s disease (IPD). J Pain Symptom Manage2006; 32: 462-469.
5.
Lee MA, Walker RW, Hildreth AJ, Prentice WMIndividualised assessment of quality of life in idiopathic Parkinson’s disease (IPD). Movement Disorders2006; 21: 1929-1934.
6.
Lee MA, Prentice WM, Hildreth AJ, Walker RWMeasuring symptom load in idiopathic Parkinson’s disease. Parkinsonism Relat Disorders2007; 13: 284-289.
7.
Ellershaw JE , Ward C.Care of the dying: the last hours or days of life. BMJ2003; 326: 30-34.
8.
Munchau A., Bhatia KPPharmacological treatment of Parkinson’s disease. Postgrad Med J2000; 76: 602-610.
9.
Obering CD, Chen JJ, Swope DMUpdate of apomorphine for the rapid treatment of hypomobility (‘off’) episodes in Parkinson’s disease. Pharmacotherapy2006; 26: 840-852.
10.
Chen JJ, Obering C.A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson’s disease. Clin Therapy2005; 27: 1710-1724.
11.
Deleu D., Hanssens Y., Northway MGSubcutaneous apomorphine: an evidence based review of its use in Parkinson’s disease. Drugs Aging2004; 21: 687-709.
12.
McGee P.Apomorphine treatment: a nurse’s perspective. ACNR2002; 2: 02.
13.
Tyne HL, Parsons J., Sinnott A., Fox S., Fletcher N., Steiger MJA 10 year retrospective audit of long term apomorphine use in Parkinson’s disease. J Neurol2004; 251: 1370-1374.
14.
Broussolle E., Marion MH, Pollak P.Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery. Lancet1992; 340: 859-860.
15.
Poewe W., Wenning GKApomorphine: an underutilised therapy for Parkinson’s disease. Mov Disord2000; 15: 789-794.
16.
Reuter I., Ellis C., Chaudhuri K.Nocturnal subcutaneous apomorphine infusion in Parkinson’s disease and restless legs syndrome. Acta Neurologica Scandinavica1999; 100: 163-167.
17.
Gonsalkorale M.Palliative care in Parkinson’s disease . CME Geriatric Med2005; 7: 22-28.
18.
Galvez-Jimenez N., Lang AEPerioperative problems in Parkinson’s disease and their management. Apomorphine with rectal domperidone. Can J Neurolog Sci1996; 23: 198-203.
19.
Nicholson G. , Pereira AC, Hall GMParkinson’s disease and anaesthesia . Br J Anaesth2002; 89: 904-916.
